Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 14.1 Exhibit 14.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- Download Excel data file
- View Excel data file
IRON similar filings
- 14 Feb 23 Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life
- 25 Jan 23 Entry into a Material Definitive Agreement
- 23 Jan 23 Entry into a Material Definitive Agreement
- 29 Dec 22 Disc Medicine Announces Completion of Merger with Gemini Therapeutics
- 28 Dec 22 Submission of Matters to a Vote of Security Holders
- 27 Dec 22 Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria
- 13 Dec 22 Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-263410) pertaining to the Gemini Therapeutics, Inc. 2021 Stock Option and Incentive Plan,
(2) Registration Statement (Form S-8 No. 333-260243) pertaining to the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan, and
(3) Registration Statement (Form S-8 No. 333-255194) pertaining to the Gemini Therapeutics, Inc. 2021 Stock Option and Incentive Plan and the Gemini Therapeutics, Inc. 2021 Inducement Plan;
of our report dated March 25, 2022, relating to the consolidated financial statements of Disc Medicine, Inc. as of and for the years ended December 31, 2021 and 2020 appearing in this Current Report on Form 8-K of Disc Medicine, Inc. (f/k/a Gemini Therapeutics, Inc.).
/s/ Ernst & Young LLP
Boston, Massachusetts
December 29, 2022